Business
Novo Nordisk's Oral Weight-Loss Drug Sees Blockbuster Debut, Fueling Investor Optimism for Stock Rebound
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.